Ember Therapeutics Inc
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport'… Read more
Ember Therapeutics Inc (EMBT) - Net Assets
Latest net assets as of September 2015: $-252.50K USD
Based on the latest financial reports, Ember Therapeutics Inc (EMBT) has net assets worth $-252.50K USD as of September 2015.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.30K) and total liabilities ($254.80K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-252.50K |
| % of Total Assets | -10968.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Ember Therapeutics Inc - Net Assets Trend (2012–2014)
This chart illustrates how Ember Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ember Therapeutics Inc (2012–2014)
The table below shows the annual net assets of Ember Therapeutics Inc from 2012 to 2014.
| Year | Net Assets | Change |
|---|---|---|
| 2014-12-31 | $-238.47K | -10.80% |
| 2013-12-31 | $-215.23K | -8.21% |
| 2012-12-31 | $-198.90K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ember Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3957400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2014)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.71K | % |
| Other Components | $2.68 Million | % |
| Total Equity | $-238.47K | 100.00% |
Ember Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Ember Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
St Elmo Silver Mines Corp
PINK:STLM
|
$0.94 |
|
Premier Power Renewable Energy Inc
PINK:PPRW
|
$0.94 |
|
Dewmar Intl Bmc Inc
PINK:DEWM
|
$0.94 |
|
USA Recycling Industries Inc
PINK:USRI
|
$0.94 |
|
Carefree Group Inc
PINK:CRFU
|
$0.94 |
|
LOUD Technologies Inc
PINK:LTEC
|
$0.94 |
|
Live Microsystems Inc
PINK:LMSC
|
$0.94 |
|
Williston Holding Company Inc
PINK:WHCA
|
$0.94 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ember Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2013 to 2014, total equity changed from -215,228 to -238,470, a change of -23,242.
- Net loss of 23,242 reduced equity.
- Other factors decreased equity by 0.
Equity Change Factors (2013 to 2014)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-23.24K | -9.75% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Ember Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-0.05 | $0.00 | x |
| 2013-12-31 | $-0.06 | $0.00 | x |
| 2014-12-31 | $-0.06 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ember Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $7.10K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $5.19K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $605.00 |
Industry Comparison
This section compares Ember Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ember Therapeutics Inc (EMBT) | $-252.50K | 0.00% | N/A | $0.94 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |